多腺苷二磷酸核糖聚合酶(PARP)抑制剂是一类利用合成致死效应来靶向DNA损伤修复缺陷肿瘤的新型靶向药物,也是第一款能够改善遗传性肿瘤患者预后的靶向治疗,彻底改变了种系BRCA1/2(gBRCA1/2)相关乳腺癌的治疗。 近日,JAMA Oncology在线发表重磅综述——“PAR...
多腺苷二磷酸核糖聚合酶(PARP)抑制剂是一类利用合成致死效应来靶向DNA损伤修复缺陷肿瘤的新型靶向药物,也是第一款能够改善遗传性肿瘤患者预后的靶向治疗,彻底改变了种系BRCA1/2(gBRCA1/2)相关乳腺癌的治疗。 近日,JAMA Oncology在线发表重磅综述——“PARP Inhibitors for Breast Cancer Treatment”,全面梳理了PARP抑制...
Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncol. 2024 Mar 21. doi: 10.1001/...
Wider access to testing for BRCA and other mutations, and to genetic counseling, are required to identify patients who could benefit from PARP inhibitor therapy. The advent of PARP inhibitors has potential benefits for BC treatment beyond the locally advanced/metastatic setting....
Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer In summary, our study presented a new class of dual PARP-1/proteasome inhibitors with significant synergistic effects for the treatment of breast cancer... H He,W Yang,Y Shi,... - 《European Jour...
2005).To date, PARP inhibitors are only approved for the treatment of advanced BRCA-mutant breast cancer leaving at least 80% of TNBC patients ineligible for this therapy. Given the limitations of current treatments, there is a crucial, unmet clinical need for developing innovative therapeutic ...
Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588–5599 (2012). CAS PubMed PubMed Central Google Scholar Shen, Y. et al. BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res....
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent manner and ... CL Speyer,JS Smith,M Banda,... - 《...
[6] Herzog TJ,Vergote I,Gomella LG,et al. Testing for homologous recombination repair or homologous recombination deficiency for poly(ADP-ribose) polymerase inhibitors:a current perspective[J]. Eur J Cancer,2023,179:136-146. [7] Tin...
directions by extending the patient population that could benefit from PARPi therapy. With demonstration of efficacy in BRCA-like phenotype TNBC, S1416 results provide a basis for expanding the therapeutic role of PARP inhibitors (e.g., veliparib) beyond germline BRCA mutation in breast cancer."...